Fundraising FoxMitsui Global Investment — 2023 Investments
1 investments dated 2023 · listed companies and verified rows first · show all
QurAlis develops precision therapies for amyotrophic lateral sclerosis (ALS) and related neurodegenerative diseases by targeting specific disease-causing genetic drivers and molecular mechanisms.
BiotechDeep TechMedical DevicesCambridge, US
Kevin Eggan(Founder, QurAlis; Group Vice President, Head of Research and Early Development, BioMarin Pharmaceutical)inRoet(Co-founder)Woolf(Co-founder)Kasper Roet(Founder, Chief Executive Officer)inShafique Virani(Executive Officer)inJason Brown(Mr. Brown is the Chief Financial Officer of the Issuer.)in
Co-investorsALS Investment FundDolby Family VenturesDroia VenturesInkefMC Healthcare VenturesMission Biocapital+8 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.